| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.034 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.035 | 0.8 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |